Pfizer Inc

NYSE: PFE
$29.42
-$0.24 (-0.8%)
Closing Price on September 20, 2024

PFE Articles

24/7 Wall St. has put together a preview of some of the major companies reporting on Tuesday, including Apple and two other Dow stocks.
Five of the Dow stocks are reporting next week, and this has the potential to sustain the run that the index has made since the Trump rally began and push it even further beyond 20,000.
The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly down.
Even though the new year is barely three weeks old, it's not too soon to take a look at how the 30 blue chip stocks included in the Dow Jones Industrial Average are faring.
Exxon Mobil, Merck, Goldman Sachs, and Pfizer sink the DJIA on Thursday.
JPMorgan, Goldman Sachs, Pfizer, and UnitedHealth sink DJIA on Tuesday.
Disney, Microsoft, Pfizer, and Intel lead DJIA to lower close on Thursday.
The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
Biotech and pharma companies were on the move Wednesday. A few of the smaller caps made tremendous gains on the day, while a couple of the major firms saw massive volume and a slight move. Although...
Major Dow Jones Industrial Average companies in the health care sector saw a relatively strong 2016, with most posting a solid gain on the year.
One strategy that has been quite common as investors rebalance and make changes each year is the Dogs of the Dow. Meet the 2017 Dogs of the Dow!
The Dow has been within 1% of 20,000 for days now. What if the Dow actually manages to hit 22,000 in 2017? It may be far more possible than most investors might imagine.
Most of the 30 components of the Dow Jones Industrial Average have risen by double-digit percentages this year. But these five stocks will keep the index from topping 20,000.
The December 15 short interest data have been compared with the previous figures, and short interest increased in most of these selected pharmaceutical stocks.
Dow 20,000 does not need all of the index's components to do well. However, these five could be a big enough drag to keep the index short of the number.